About the group


Research projects of the group

Genetic analysis of susceptibility to childhood tumours and pharmacogenetic analysis of response to therapy

At the Department of Genetics, Cell- and Immunobiology there is a human data- and DNA biobank consists of DNA from 626 childhood acute lymphoblastic leukaemia (ALL), 93 childhood osteosarcoma and 70 testicle tumour patients and hundreds of healthy controls. In the databank we collected the patients clinical (medical and laboratory diagnostic) data at the diagnosis, and during the treatment until the end of the therapy. We recorded certain drug levels, side effects (regarding the cardiovascular system, nervous system, etc.) and in the case of some side effects follow up data after the treatment. Genetic polymorphisms in genes of drug metabolic enzymes, drug transporters and drug targets can influence the efficacy and even the effect of the medication. Gene polymorphisms can modify the necessary medicine amount for the optimal response and contribute to the development of side effects. In our research we study the relationship between the genetic polymorphisms of the above mentioned genes and the clinical data of the patients in our databank. We search for polymorphisms significantly influencing the response to therapy and the course of the disease. One group of these studied genes is the adenosine triphosphate binding casette (ABC) transporter superfamily. Several members of this superfamily are known to be expressed also in tumor cells and they are important in the transport of chemotherapic drugs across the cell membrane. Among these the best-known are the ABCB1 (ATP-binding cassette, sub-family B, member 1 or MDR1: multiple drug resistance 1) and ABCG2 (ATP-binding cassette, sub-family G, member 2), but many other genes involved in this process belong to ABC-transporters. The polymorphisms of thecytochrome p450 (CYP) gene family and different gene variants of other drug metabolic enzymes are also relevant in the chemotherapy treatment response. One of the most crucial aims of our research is to contribute to the new, relevant pharmacogenetic results of personalized therapy. Before finding the adequate therapy method, the physicians should determine the genotype of the patients to get a better outcome, and reduce the toxic side effects.

We also examine the inheritable susceptibility of tumourigenesis (ALL, osteosarcoma, testicle cancer). It is known, that in some family lines definite tumour incidence is more prevalent. It confirms that the susceptibility of disease development has genetic components too. The above-mentioned genes (e.g. ABCB1, ABCG2, CYP) have significant role in the transport ofxenobiotics, that can cause mutation in genes. The dysfunction of the MTHFR(member of the folic acid metabolic pathway), and GST (glutathione S-transferases, genes of redox system) gene family can also contribute to the development of the disease.

 

Genomic investigation of asthma with animal experiments and examinations of human samples

The asthma genetics research group conducts research to gain insight into the genetic background of asthma and the molecular biological patterns influencing the asthma pathomechanism by use of human samples and animal disease models. In these studies the group has succeeded in proving numerous genes, genetic variations and biological pathways contributing to the asthma phenotype.

Since 2006 due to our infrastructural development we are able to carry out high-throughput screenings, population genetic tests and microarrayexperiments to validate the SNP results.

Our Institute stores Hungary's largest asthma-allergy biobank which consists of clinical, laboratory data and DNA samples of 425 asthmatic, 304 allergic and 500 healthy children. In the future we aim to continuously enlarge our biobank by involving foreign samples also.

One of our scientific goals is the detailed mapping of genomic regions previously identified in asthma pathomechanism and the consequent genotyping of the newly identified polymorhisms on our biobank. Apart from the already characterized 11q13 region we plan to thoroughly investigate the genomic regions 14q22 and 17q1. Furthermore, we aim to analyze the polymorphisms of candidate genes identified by animal studies or literature data mining. The SNP searching and selecting procedure is directed by software developed by our group.

Our research group previously completed a whole genome gene expression microarray analysis (Agilent Whole Mouse Genome Oligo Microarray 44K chips were used) of OVA induced mouse model of asthma to follow the lung gene expression profile change in four state of the progression of mouse allergic airway inflammation. Microarray analysis revealed some new potential previously not investigated candidate genes which showed significantly changed gene expression profile during allergic progression. Out of these genes presently the study of paraoxonase 1 (PON1) is going on.

The examinations of human polymorphisms, selected genes from animal experiments and their role in asthma pathogenesis are carried out with the following protocol:

(I) Selection of genes according to the results of animal experiments. We favor previously not studied genes showing markedly changed gene expression during the disease progression.

(II) Identification of SNPs with bioinformatic methods and examination of their role with association studies on our biobank.

(III) Investigation of gene function on human samples. Experiments carry out according to known, revealed and supposed function of genes. Following studies are planning: gene and protein expression in lung (asthmatics vs. healthy subjects); enzyme activity in different samples and activity changes e.g. serum level during treatment; reveal the influencing factors (e.g. disease, smoking, age, drugs, treatment etc.) of gene and/or protein function

            Our purpose with the above-mentioned examinations is to identify genes, genetic polymorphisms implicated in asthma pathomechanism or susceptibility. The realization of our aims could lead to the understanding of asthma development and further result in exploration of new therapy targets which could contribute to work out more effective and wide-ranging therapies for both patients and doctors.

 

Genetics of obesity

Obesity has become a major public health problem in most developed countries. According to some data 60% of the Hungarian population isoverweight or obese. It is well known that obesity is a risk factor for type 2 diabetes, dyslipidemia, hypertension, and atherosclerosis. The etiology of obesity is complex and consists of the interaction of genetics, diet and physical activity, additionally influenced by environmental, socioeconomic and behavioral factors. It is a metabolic disorder with energy balance disturbance, which is manifested in elevated nutrition or in decreased energy expenditure, and leads to fat accumulation. During the pathogenesis of obesity not only the fat storage increase but the size and number of adipose cells too.

Traditionally, adipose tissue was considered to passively store triacylglycerols and release free fatty acids, but it is now recognized as an active endocrine organ that produces a large number of bioactive mediators, which are interact with immune- and cardiovascular systems.

 

At the Department of Genetics, Cell- and Immunobiology we have examined the genetic background of obesity since 2007. The project is granted partly by ETT and partly by the NKTH, in which we participated as a member of the Obekon Consortium.

One of the most crucial aims of our research is to explain the pathogenesis of obesity by monitoring the DNA and transcriptional changing in human samples and animal models. In our research we study the genes influencing the pathomechanism of obesity, their polymorphisms, and the molecular disease pathways.

 

Developing Bioinformatics Tools

The Department of Genetics, Cell- and Immunobiology (DGCI) at Semmelweis University cooperates with Department of Measurement and Information Systems (DMIS) at Budapest University of Technology and Economics since 2005. The colleagues of the two departments work together on developing various bioinformatics methods that can accelerate the disease specific (e.g. asthma, acute lymphoblastic leukaemia, childhood tumors) genetic research in DGCI.

The bioinformatics tools and methods developed at DMIS can be utilized in two main areas: (i) they help in the economical designing of the investigations of the genomics laboratory so the investigations on the available samples should provide the most information with the least possible cost. (ii) On the other hand the exhaustive evaluation of the datasets provided by the genetic investigations and the design of further genetic investigations based on that information need complex bioinformatics apparatus.

The inter-individual difference in genetic background between two patients can considerably influence the effects of specific treatments. Identifyingbiomarkers connected with the expected effectiveness of treatments can be an important milestone on the road of personal genomics. Investigating the different responds to treatments can sometimes lead to the discovery of a combination of genetic variants which can be utilized to predict with great certainty the effectiveness of the specific treatment or drug on a new patient. Achievement of this goal can be influenced by numerous factors: the a prior knowledge of the effect of treatment, the nature of effect and the factors concerning it, the sampling protocol, the size of biobank and the type and quality of information assigned to the samples, examining the appropriate genomic regions, the type of instruments used for genomic measurements, the quality of information provided by these instruments and the type of statistical methods used for evaluating the data. While precise biological interpretation of the different responds to the specific treatment is very difficult especially in case of multifactorial diseases, to discover statistically efficient biomarkers can be a realistic goal in most cases. Our team's main aim is to find the factors influencing the discovery of biomarkers used for treatment selection and to find or develop the bioinformatics tools and medical biologic methodology that can be efficiently used for biomarker discovery. We aim to develop general methodology and protocols but we mainly focus on diseases already examined by DGCI and DMIS (e.g. asthma, acute lymphoblastic leukemia).

The bioinformatics methods developed by our team are based on the Bayesian statistical framework. It offers a normative way for knowledge representation and for learning from observations. Concerning utility theory the Bayesian framework can be used to make optimal decisions. It establishes an important connection between statistics and knowledge engineering because it is capable to incorporate heterogeneous a prior knowledge into the statistical learning process. Besides these, Bayesian framework provides a computational framework for the learning and using of complex probabilistic models because it enables the using of various stochastic simulation methods. This finally results in the appearance of computation-intensive statistics.

Bayesian Multilevel Analysis (levels: bivariate, multivariate, interaction, causal domain model) is a new, promising general method, which can be very useful in case of datasets with small sample sizes and multiple testing problems. Bayesian methods are effectively used in the field of genetic association studies (GAS). In the Bayesian framework, Bayesian belief networks (which are computationally intensive) have many advantages: (i) discovery of direct associations, (ii) multivariate management of missing variables, (iii) the ability to incorporate various types of a prior knowledge and (iv) discovery of causal effects and relationships.

The bioinformatics project is granted by the NKTH, in which we participate as a member of the Genagrid Consortium (http://www.genagrid.com/).

 

Collaborations:

  • GenaGrid consortium:
    • Department of Measurement and Information Systems of Budapest University of Technology and Economics
    • MTA KFKI Research Institute for Particle and Nuclear Physics
    • Silicon Computers Ltd.
    • Csertex Ltd.
  • Heim Pal Hospital
  • Department of 1st Pediatrics, Semmelweis University
  • Department of Pulmonology, Semmelweis University
  • Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey SM2 5NG, UK

 

Running grants

  • NKTH TECH_08-A1/2-2008-0120; Bioinformatic services for genetic association studies using high-performance grid computation; 2009-2012; 570,625,000 Ft
  • OTKA K81941 Comprehensive study of the pathogenesis of severe asthma 35,946,000 Ft
  • OTKA K75782 Single nucleotide polymorphisms in hypodontia; 2008-2011; 19,796,000 Ft
  • OTKA K72689 Analysis of interactions between inflammatory and vasoregulatory pathways in chronic heart failure: application of logical analysis of data, a novel data-mining tool; 2008-2011; 54,000,000 Ft
  • OTKA K72385 Polymorphism studies of genes potentially involved in the development of periodontitis; 2008-2012; 25,374,000 Ft
  • ETT 415/2009  Genomic investigations in asthma in human samples and animal models; 2009-2011; 3.600,000 Ft
  • ETT 464/2009 mRNA and microRNA expression profiling of human adipose tissue to predict the development or avoidance of complications of obesity; 2009-2011; 3,000,000 Ft
 

Members

Leader:


  SzalaiC

Dr. Csaba Szalai, University Professor

Members:


  Kutszegi Nora

Nóra B. Kutszegi, PhD Student

  Sagi Judit

Dr. Judit Cs. Sági, PhD Student

 

  Semsei Agnes

Dr. Ágnes F. Semsei, Assistant lecturer

  no profile image Zsófia Gál, PhD Student
  Gezsi Andras

Dr. András Gézsi, Research Fellow

  Vangor Monika

Mónika S. Vángor, Assistant

 

 

Publications


2014

 

2013

 

2012

  • A gyermekkori akut limfoid leukémia farmakogenetikája egy gyógyszermellékhatás példáján.
    Semsei A, Lautner-Csorba O, Kutszegi N, Schermann G, Eipel O, Falus A, Szalai C, Kovács GT, Erdélyi D.  
    MAGYAR TUDOMÁNY:(6) pp. 90-97. (2012)
  • Relationship between air pollution, NFE2L2 gene polymorphisms and childhood asthma in a Hungarian population. 
    Ungvári I, Hadadi É, Virág V, Nagy A, Kiss A, Kalmár Á, Zsigmond G, Semsei ÁF, Falus A, Szalai C.
    J Community Genet, 2012 Jan;3(1):25-33. Epub 2011 Dec 30. IF.: 1,538
  • Asthma endophenotypes and polymorphisms in the histamine receptor HRH4 gene. 
    Simon T, Semsei ÁF, Ungvári I, Hadadi É, Virág V, Nagy A, Vángor MS, László V, Szalai C, Falus A.
    Int Arch Allergy Immunol. 2012 May 30;159(2):109-120. IF.: 2,54
  • Implication of BIRC5 in asthma pathogenesis.
    Ungvári I, Hadadi É, Virág V, Bikov A, Nagy A, F. Semsei ÁF, Gálffy G, Tamási L, Horváth I, Szalai C.  
    Int Immunol, 2012 May;24(5):293-301. IF.: 3,301
  • Evaluation of a partial genome screening of two asthma susceptibility regions using Bayesian network based Bayesian multilevel analysis of relevance.
    Ungvári I, Hullám G, Antal P, Kiszel SP, Gézsi A, Hadadi É, Virág V, Hajós G, Millinghoffer A, Nagy A, Kiss A, Semsei ÁF, Temesi G, Melegh B, Kisfali P, Széll M, Bikov A, Gálffy G, Tamási L, Falus A, Szalai C.  
    PLoS One. 2012;7(3):e33573. Epub 2012 Mar 14. PubMed PMID: 22432035; PubMed Central PMCID: PMC3303848. IF.: 4,411
  • Non-synonymous single nucleotide polymorphisms in genes for immunoregulatory galectins: Association of galectin-8 (F19Y) occurrence with autoimmune diseases in a Caucasian population. 
    Pál Z, Antal P, Srivastava SK, Hullám G, Semsei AF, Gál J, Svébis M, Soós G, Szalai C, André S, Gordeeva E, Nagy G, Kaltner H, Bovin NV, Molnár MJ, Falus A,Gabius HJ, Buzás EI.
    Biochim Biophys Acta. 2012 Jun 7;1820(10):1512-1518. IF.: 4,663
  • Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance. 
    Lautner-Csorba O, Gézsi A, Semsei AF, Antal P, Edélyi DJ, Schermann G, Kutszegi N, Csordás K, Hegyi M, Kovács G, Falus A, Szalai C.
    BMC Med Genomics. 2012 Sep 28;5(1):42. IF.: 3,69
  • ABCC1 polymorphisms in anthracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia. 
    Semsei AF, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi MZ, Kiszel PS, Lautner-Csorba O, Szabolcs J, Masat P, Fekete G, Falus A, Szalai C, Kovacs GT.
    Cell Biol Int. 2012; 36: 79-86. IF.: 1,747
  • Candidate Gene Association Study in Childhood Acute Lymphoblastic Leukemia
    Lautner-Csorba O, Semsei AF, Gezsi A, Kutszegi N, Falus A, Szalai C 
    European Journal of Cancer 2012: 48, S278
  • Genetic Risk Factors of Neurotoxicity During Chemotherapy
    Semsei A, Lautner-Csorba O, Schermann G, Kutszegi N, Falus A, Kovacs G, Szalai C  
    European Journal of Cancer 2012: 48, S236
  • Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. 
    Hegyi M, Gulácsi A, Cságoly E, Csordás K, Eipel OT, Erdélyi DJ, Müller J, Nemes K, Lautner-Csorba O, Kovács GT.
    J Cancer Res Clin Oncol. 2012 Oct;138(10):1697-702.

 

2011

  • Teljes genom asszociációs vizsgálat. 
    Szalai C.
    Orvostovábbképző szemle. 2011;9:64-72.
  • A súlyos asztma hazai előfordulása és klinikai fenotipizálása. 
    Csoma Z, Antus B, Barta I, Szalai C, Strausz J, Kovács G, Herjavecz I.
    Medicina Thoracalis. 2011; LXIV (5): 299-311.
  • Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia. 
    Sherborne AL, Hemminki K, Kumar R, Bartram CR, Stanulla M, Schrappe M, Petridou E, Semsei AF, Szalai C, Sinnett D, Krajinovic M, Healy J, Lanciotti M, Dufour C, Indaco S, El-Ghouroury EA, Sawangpanich R, Hongeng S, Pakakasama S, Gonzalez Neira A, Leal Ugarte E, Peralta Leal V, Meza Espinoza JP, Kamel AM, Radwan ER, Ebid GT, Yalin S, Yalin E, Berkoz M, Simpson J, Roman E, Lightfoot T,Hosking FJ, Vijayakrishnan J, Greaves M, Houlston R.
    Haematologica. 2011 Jul;96(7):1049-54. IF.: 6.416
  • Decision Making & Problem Soving-Acute Lymphoblastic Leukemia-Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia
    Sherborne AL, Hemminki K, Kumar R, Bartram CR, Stanulla M, Schrappe E, Szalai C ...
    Haematologica-the Hematology Journal 2011: 96 (7), 1049
  • Clinical Importance of Methotrexate Pharmacokinetics and Pharmacogenetics in Pediatric Osteosarcoma
    Hegyi MZ, Gulacsi A, Semsei AF, Cságoly E, Erdelyi D, Szalai C, Kovacs GT.
    European Journal of Cancer 2011: 47, S287
  • Lack of evidence for association of two functional SNPs of CHI3L1 gene (HC-gp39) with rheumatoid arthritis. 
    Srivastava SK, Antal P, Gál J, Hullám G, Semsei AF, Nagy G, Falus A, Buzás EI.
    Rheumatol Int. 2011 Aug;31(8):1003-7.
  • Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. 
    Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss J, Szendroi M, Csoka M, Kovacs G.
    Pediatr Blood Cancer. 2011Sep;57(3):415-22.  

 

2010

  • Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed. 
    Szabó PM, Tamási V, Molnár V, Andrásfalvy M, Tömböl Z, Farkas R, Kövesdi K, Patócs A, Tóth M, Szalai C, Falus A, Rácz K, Igaz P. 
    Oncogene. 2010 May 27;29(21):3163-72; doi:10.1038/onc.2010.80; IF.: 7.216
  • Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. 
    Sherborne AL, Hosking FJ, Prasad BR, Kumar R, Rolf Koehler R, Vijayakrishnan J… Szalai C, Semsei AF, Erdelyi DJ, et al.
    Nat Genet. Epub 2010 May 9; DOI 10.1038/ng.585; 2010: 42; 492-494. IF.: 30.259
  • Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. 
    Triglyceride Coronary Disease Genetics Consortium (Szalai C et al) and Emerging Risk Factors Collaboration.
    Lancet. 2010 May 8;375(9726):1634-9. IF.: 28.409
  • Az asztma genomikai háttere. 
    Szalai C.
    Lege Artis Medicine 2010:20(12).
  • Strengths and weaknesses of gene association studies in childhood acute lymphoblastic leukemia. 
    Semsei AF, Antal P, Szalai C.
    Leuk Res. 2010: 34:269-271. IF.: 2,483
  • Genetikai alapok. 
    Szalai Cs.
    In: Atherosclerosis (szerk.: Császár Albert); Medicina Kiadó; 2010: pp 139-160.
  • Examination of GST and CCR5 gene polymorphisms in children with acute lymphoid leukemia in Hungarian population 
    Csorba O, Semsei AF, Erdélyi DJ, Barabás E, Vángor MS, Schermann G, Hadadi E, Szalai C.
    Ejc Supplements 2010: 8 (5), 18-18
  • ABCC1 polymorphisms in antracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia 
    Semsei A, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi M, Csorba O, Falus A, Szalai C.
    Ejc Supplements 2010: 8 (5), 71-71.
  • Clinical importance of GGH− 401C> T and the RFC1 A (80) G polymorphism in children with osteosarcoma 
    Hegyi MZ, Semsei AF, Csagoly E, Erdelyi D, Szalai C, Kovács G. 
    Ejc Supplements 2010: 8 (5), 68-68

 

2009

  • Gene expression profiling of experimental asthma reveals a possible role of paraoxonase-1 in the disease. 
    Tölgyesi G, Molnár V, Semsei ÁF, Kiszel P, Ungvári I, Pócza P, Wiener Z, Komlósi ZI, Kunos L, Gálffy G, Losonczy G, Seres I, Falus A, Szalai C.
    Int Immunol. 2009 Aug;21(8):967-75. Epub 2009 Jun 25. IF.: 3,290
  • Genomika a mai modern gyógyszerkutatásban I. rész. 
    Szalai Cs.
    Gyógyszerészet 2009;53:331-337.
  • Genomika a mai modern gyógyszerkutatásban II. rész. 
    Szalai Cs.
    Gyógyszerészet 2009;53:391-396.
  • Evaluation of methods in GA studies: yet another case for Bayesian network. 
    Hullám G, Antal P, Szalai C, Falus A. 
    Machine Learning in System Biology 2009 (MLSB09), Proc. of the Third International Workshop, 2009: 35-44.
  • A bioinformatic platform for a Bayesian, multiphased, multilevel analysis in immunogenomics. 
    Antal P, Millinghoffer A, Hullam G, Hajós G, Szalai C, Falus A.
    In D.R.Flower M.N.Davies, S.Ranganathan, editor, Bioinformatics for Immunomics, pp 157-185. –. Springer. 2009.
  • Allergiás kórképek genetikai vonatkozásai. 
    Szalai Cs.
    In. Gyakorlati allergológia (szerk. Temesvári Erzsébet és Kárpáti Sarolta); Semmelweis Kiadó; 2009: pp. 339-354.
  • Influence of the GGH− 401C> T and the RFC1 A (80) G polymorphism on methotrexate toxicity in children with osteosarcoma 
    Hegyi MZ, Semsei AF, Cságoly E, Bácsi K, Erdélyi D, Szalai C, Kovacs GT. 
    European Journal of Cancer Supplements 2009: 7 (2), 224

 

2008

  • Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. 
    Erdélyi DJ, Kámory E, Csókay B, Andrikovics H, Tordai A, Kiss C, Semsei AF, Janszky I, Zalka A, Fekete G, Falus A, Kovács GT, Szalai C.
    Pharmacogenomics J. 2008 8: 321-327. IF.: 5,435
  • Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. 
    Semsei AF, Erdélyi DJ, Ungvári I, Kámory E, Csókay B, Andrikovics H, Tordai A, Cságoly E, Falus A, Kovács GT, Szalai C.
    Leukemia Res. 2008 Aug;32(8):1214-20.IF.: 2,483
  • Asthma from a pharmacogenomic point of view. 
    Szalai C, Ungvári I, Pelyhe L, Tölgyesi G, Falus A.
    Brit J Pharmacol.2008 Apr;153(8):1602-14. IF.: 4,902
  • A Bayesian View of Challenges in Feature Selection: Multilevel Analysis, Feature Aggregation, Multiple Targets, Redundancy and Interaction. 
    Antal P, Millinghoffer A, Hullám G, Szalai C. Falus A.
    JMLR W&P 2008: 4:74-89.
  • Az MCP-1 G/A és a T-bet C/G polimorfizmusok vizsgálata primer Sjögren-szindrómában és SLE-ben. 
    Kovács A, Koncz Á, Endreffy E, László A, Petri I, Eller J, Szalai C.
    Magyar Immunológia 2008;7(1-2): 30-36.
  • Human tumor necrosis factor alpha gene polymorphism in Hungarian patients with primary Sjörgen syndrome. 
    Kovács A, Koncz Á, Szalai C, Petri I,  László A,  Endreffy E.
    Magyar Immunológia 2008;7(4): 12-17.

 

2007

  • Az asztma genomikája és farmakogenomikája. 
    Nagy A, Szalai C.
    Gyermekgyógyászat. 2007;58: 124-129.
  • Frequency of carriers of 8.1 ancestral haplotype and its fragments in two Caucasian populations. 
    Kiszel P, Kovacs M, Szalai C, Yang Y, Pozsonyi E, Blasko B, Laki J, Prohaszka Z, Fazakas A, Panczel P, Hosszufalusi N, Rajczy K, Wu YL, Chung EK, Zhou B, Blanchong CA, Vatay A, Yu CY, Fust G. 
    Immunol Invest. 2007;36(3):307-19. IF.: 1,276
  • The HLA 8.1 ancestral haplotype is strongly linked to the C allele of -429T > C promoter polymorphism of receptor of the advanced glycation endproduct (RAGE) gene. Haplotype-independent association of the -429C allele with high hemoglobinA1C levels in diabetic patients. 
    Laki, J.Kiszel, P.Vatay, A.Blaskó, B. Kovács, M. Körner, A. Madácsy, L. Blatniczky, L. Almássy, Z. Szalai C, Rajczy, K. Pozsonyi, E. Karádi, I. Fazakas, A. Hosszúfalusi, N. Pánczél, P. Arason, G.J. Wu, Y.-L. Zhou, B. Yang, Y. Yu, C.-Y. Füst, G.
    Molecular Immunology Volume 44, Issue 4, January 2007, Pages 648-655  IF.: 4,768
  • CCR5Δ32 mutation, Mycoplasma pneumoniae infection and asthma. 
    Ungvári I, Tölgyesi G, Semsei AF, Nagy A, Radosits K, Keszei M, Kozma G, Falus A, Szalai C.
    J Allergy Clin Immunol. 2007 Jun;119(6):1545-7. Epub 2007 Apr 18, IF.: 8,829.
  • Chlamydophila pneumoniae infection status is dependent on the subtypes of asthma and allergy.
    Nagy A, Keszei M, Kis Z, Budai I, Tölgyesi G, Ungvári I, Falus A, Szalai C.
    Allergy Asthma Proc 2007;28:58-63. IF.: 0.763
  • The effects of transporter gene polymorphisms on the immunosuppressive   effects of chemotherapy in childhood acute lymphoblastic leukemia (ALL).
    Kovacs GT, Erdelyi DJ, Semsei A, Kamory E, Csoka M, Tordai A, Szalai C.  
    BLOOD REVIEWS. 2007;21:S67.
  • Imbalance of the C4A and C4B genes dosage as a robust risk factor for premature cardiovascular disease morbidity and mortality 
    G Füst, M Sasvári, B Blaskó, C Szalai, R Ádány, C Yu, GJ Arason.
    Molecular Immunology 2007: 44 (1), 173.

 

2006

  • The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia. 
    Erdelyi DJ, Kamory E, Zalka A, Semsei AF, Csokay B, Andrikovics H, Tordai A, Borgulya G, Magyarosy E, Galantai I, Fekete G, Falus A, Szalai C, Kovacs GT. 
    Cell Immunol. 2006 Dec;244(2):121-4. IF.: 1,709
  • Genomic strategies in pharmacology of asthma and autoimmunity. 
    Szalai C, Buzás E, Fülöp AK, Kőhidai L, Falus A.
    Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 2006;5:383-399.
  • Involvement of TNFa-308A promoter polymorphism in the development of asthma in children infected with Chlamydophila pneumoniae. 
    Gergely Tölgyesi, Márton Keszei, Ildikó Ungvári, Adrienne Nagy, András Falus, Csaba Szalai. 
    Pediatr Res. 2006 Nov; 60(5):543-8. IF.: 2,875
  • Az asztma farmakogenomikája, jelen és perspektíva, összefoglaló közlemény. 
    Szalai C, Tölgyesi G, Nagy A, Falus A.
    Orv Hetil. 2006 Jan 29;147(4):159-69.
  • C4BQ0, EGY GÉNVARIÁNS, AMELY JELENTŐSEN CSÖKKENTI AZ ESÉLYT AZ EGÉSZSÉGES ÖREGKOR MEGÉLÉSÉRE. 
    Füst György, Kramer Judit, Kiszel Petra, Blaskó Bernadette, Szalai Csaba, Gudmundur Johann Arason, Chack Yung Yu .
    Magyar Tudomány, 2006/3 266. o.
  • Pediatric asthmatic patients have low serum levels of monocyte chemoattractant protein-1.
    Márton Keszei, Adrienne Nagy, Gergely T Kozma, Károly Radosits, Gergely Tölgyesi, András Falusand Csaba Szalai:
    J Asthma  2006 Jun-Jul;43(5):399-404. IF.: 1.476
  • Rendszerszemléletű biológia: a jövő orvosbiológiai kutatási paradigmája; az immungenomika példája kapcsán. 
    Falus A, Molnár MJ, Szalai C.
    Orvosképzés 2006;1:3-10.
  • Az allergia genomikája. 
    Szalai Cs.
    In: Fejezetek a genom-léptékű biológiából és orvostudományból (szerk. Falus A) Semmelweis Kiadó 2006: pp. 349-360.
  • A genom számítógépes vizsgáló módszereinek alapjai
    Szalai Cs.
    In: Fejezetek a genom-alapú biológiából és orvostudományból (szerk. Falus A.) Semmelweis Kiadó 2006: pp. 9-15

 

2005

  • Az asztma genomikai háttere. 
    Szalai Csaba:
    Magyar Tudomány. 2005;6:700-7.
  • Az atópiás légúti betegségek genomikai háttere. 
    Szalai Cs.
    In: Légúti allergológia. Asztma és társbetegségei. (szerk. Herjavecz Irén). Melania Kiadó. 2005: pp.17-34.
  • Genomic investigation of asthma in human and animal models. 
    Szalai C.
    In: Immunogenomics and Human Disease. (Ed. Falus A) John Wiley & Sons Ltd. London. 2005; pp. 419-441. 
  • The MHC II (HLA) and III (TNFa) genotypes in type 1 diabetic children and their relatives.
    Vatay, A; Pozsonyi, E; Rajczy, K; Laki, J,  Fust, G,  Blatniczky, L,  Almassy, Z,  Andrasi, K,  Szalai, C,  Karadi, I,  Romics, L,  Panczel, P.
    GENES AND IMMUNITY, 6: S34-S34 Suppl. 1 APR 2005

 

2004

 

2003

 

2002

 

2001

 

 

Conferences


Semmelweis Egyetem PhD Tudományos Napok 2009 

2009. március 30-31. Budapest SE NET

  • Ágnes F. Semsei, Dániel Erdelyi, Ildikó Ungvári, Edit Cságoly, Márta Z. Hegyi, András Millinghoffer, Gábor Hullám, Péter Antal, András Falus, Gábor Kovács, Csaba Szalai: The role of ATP-binding cassette transporter polymorphisms on antracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia

  

MTA 2009. évi közgyűléséhez kapcsolódó tudományos előadás
MTA Székház, 2009. május 6.

  • Szalai Csaba: Asthma genomika

  

Human Genome Variation Society, Human Variome Project, Towards Establishing Standards
22nd May 2009, Vienna, Austria

  • P.Antal, G. Hajós, G.Hullám, A.Millinghoffer C. Szalai and A. Falus:Adaptive Sequential Partial Genome Screening Studies: a Case Study in Asthma

 

Allergy & Asthma Symposium: Bridging Innate and Adaptive Immunity
May 28-29, 2009 Bruges, Belgium

  • Petra Sz. Kiszel, Ágnes F. Semsei, Ildikó Ungvári, Adrienne Nagy, Márta Széll, Béla Melegh, Péter Kisfali, Péter Antal, Gábor Hullám, András Falus, Csaba Szalai: Screening for susceptibility genes of asthma on chromosome 11 and 14

 

Genetikai Műhelyek Magyarországon
MTA Szegedi Biológiai Központ; Szeged, Temesvári krt. 62. 2009. szeptember 11. 

  • F. Semsei Ágnes, Sz. Kiszel Petra, Erdélyi Dániel, Ungvári Ildikó, Hegyi Márta, Cságoly Edit, Falus András, Kovács Gábor, Szalai Csaba:Genomikai és farmakogenomikai kutatások gyermekkori asztma és akut limfoid leukémia területén, valamint az SNP Core Facility bemutatása

  

Machine Learning in System Biology 2009 (MLSB09)
Sept 5-6, Ljubljana, Slovenia

  • P. Antal, A. Millinghoffer, C. Szalai, A. Falus: On the Bayesian applicability of graphical models in genome-wide association studies.
  • G. Hajós, P. Antal, Y. Moreau, C. Szalai, A. Falus: Variable Pruning in Bayesian Sequential Study Design.
  • P. Antal, P. Sárközy, Z.Balázs, P. Kiszel, A. Semsei, C. Szalai, A. Falus:Averaging over measurement and haplotype uncertainty using probabilistic genotype data.

 

ECCO15-ESMO34 Congress
2009 szeptember 20-24 Berlin, Németország

  • Márta Z. Hegyi, Ágnes F. Semsei, Edit Cságoly, Krisztián Bácsi, Dániel Erdélyi, Csaba Szalai, Gábor Kovacs Influence of the GGH -401C>T and the RFC1 A(80)G polymorphism on methotrexate toxicity in children with osteosarcoma

 

PHARMACOGENOMICS & PERSONALIZED MEDICINE
September 12 - 15, 2009, Wellcome Trust Conference Centre, Hinxton, UK

  • Ágnes F. Semsei, Dániel Erdélyi, Ildikó Ungvári, Edit Cságoly, Márta Z. Hegyi, András Millinghoffer, Gábor Hullám, Péter Antal, András Falus, Gábor Kovács, Csaba Szalai: The role of ATP-binding cassette transporter polymorphisms on antracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia

 

2nd Central European Congress on Obesity
1st-3rd October 2009, Budapest

  • Csaba Szalai, Ágnes F. Semsei, Ildikó Ungvári, Petra Kiszel, Péter Antal, András Falus. Investigation of the genomic background of obesity using single nucleotide polymorphism analysis in candidate genes
  • K. Éder, I. Likó, A. Falus. Obesity related mRNA and miRNA profiling

  

Sarasota splash: Update in Biomedical and Clinical Sciences The Helmsley Sandcastle Hotel Sarasota, Lido Beach Florida 41st Annual Scientific Meeting of HMAA
October 25 - October 30, 2009   

  • Csaba Szalai, Gergely Tölgyesi, Viktor Molnár, Ágnes F. Semsei, Petra Kiszel, Péter Pócza, Zoltán Wiener, Zsolt I. Komlósi, Gabriella Gálffy, László Kunos, György Losonczy, András Falus: Gene expression profiling of experimental asthma reveals a possible role of paraoxonase-1 in the disease
  • Peter Antal, G. Hullam, Cs. Szalai, A. Falus: A "Bayesian Tour" from Study Design through Data Analysis to Clinical Decision Support

 

Late Effects in Cancer Survivors 
2010 március 3-4. Cutler's Hall, Sheffield, UK

  • Dániel J. Erdélyi, Ágnes F. Semsei, Ildikó Ungvári, Edit Cságoly, Márta Hegyi, Péter Masát, Judit Szabolcs, György Fekete, András Falus, Csaba Szalai, Gábor Kovács. Investigation of ABCC1 polymorphisms in anthracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia

 

3rd  HUNGARIAN-SINGAPOREAN WORKSHOP on SYSTEMS BIOLOGY and COMMUNICATION SYSTEMS  
Budapest, March 29-30, 2010

  • Peter Antal, G. Hullam, Cs. Szalai, A. Falus: A "Bayesian Tour" in Omics

  

12th International Paediatric Haematology and Oncology Update Meeting 
Edinborough, UK, 2010 április 29-30.

  • Dániel J. Erdélyi, Ágnes F. Semsei, Ildikó Ungvári, Edit Cságoly, Márta Hegyi, Péter Masát, Judit Szabolcs, György Fekete, András Falus, Csaba Szalai, Gábor Kovács. Investigation of ABCC1 polymorphisms in anthracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia

  

MLDT 55. Nagygyűlése 
Pécs 2010. augusztus 26-28.

  • Szalai Cs., Semsei F. A., Erdelyi D., Csorba O., Vángor M., Falus A., Kovacs G. Investigat ion of ABCC1 polymorphisms in anthracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia
  • Hadadi E., Virag V, Szalai Cs. Investigation of 96 single nucleotide polymorph isms in 47 asthma genes selected from the scientific literature for association with asthma
  • Semsei F. A., Erdelyi D. J, Lautner-Csorba O., Vangor M., Falus A., Kovacs G., Szalai Cs. Genetic polymorphisms in anthracycline induced cardiotoxicity in Pediatric acute lymphoblastic leukemia
  • Csorba O., Semsei F. A., Szalai Cs.  Examination of GS T and CCR5 gene polymorphisms in children with acute lymphoid leukemia in Hungarian population
  • Virag V., Hadadi E., Szalai Cs. SIGNIFICANTLY ALTERED EXPRESSION IN AN ANIMAL MODEL CAUSED BY SINGLE NUCLEOTIDE POLYMORPHISMS IN 59 GENES HAVE ALSO A ROLE IN HUMAN ASTHMA

 

Magyar Biokémiai Egyesület 2010. évi Vándorgyűlése
Semmelweis Egyetem Elméleti Orvostudományi Központja; 2010. augusztus 25-28.

  • Gézsi A., Antal P., Hajós G., Millinghoffer A., Szalai Cs., Falus A.: Bayesi módszerek felskálázásának vizsgálata teljes genom asszociációs elemzésekben
  • Temesi Gergely, Antal Péter, Szalai Csaba, Falus András, Hajós Gergely, Gézsi András, Sárközy Péter, Marx Péter: Több forrásból származó omikai adatok és információk kiértékelése hibrid tudásbázis technológiával"
  • Antal P., Hajós G., Millinghoffer A., Hullám G., Balázs Z., Gézsi A., Temesi G., Sárközy P., Félné Semsei Á, Ungváry I., Németh Zs., Virág V., Hadadi É., Debreceni G., Kormos K., Lévai P, Szalai Cs., Falus A.: Genagrid bioinformatikai szolgáltatás genetikai asszociációs elemzések támogatására
  • Hajós Gergely, Antal Péter, Szalai Csaba, Falus András: Bayes-háló alapú adaptív kísérlettervezés parciális genomszűrési kísérletekhez
  • Marx, P. Antal, G. Hullám, A. Millinghoffer, Cs. Szalai, A. Falus: Sorrendi fúziós algoritmusok alkalmazása klinikai genomikában
  • Sárközy P., Antal P., Balázs Z., Sasvári M., Szalai Cs., Falus A.: A bizonytalan genotípusos és in silico rekonstruált haplotípusos adatok elemzésének lehetőségei modell átlagolással

  

CSCDA 2010
Leuven (Belgium), 25-27 August 2010

  • Antal, P. Marx, A. Millinghoffer, G. Hullam, I. Ungvary, Cs. Szalai, A. Falus: Bayesian fusion of heterogeneous signs for biomarker and pathway discovery, Capita Selecta in Complex Disease Analysis

 

Magyar Humángenetikai Társaság VIII. kongresszusa 
2010, szept. 2-4, Debrecen

  • P. Antal, P. Sárközy, G. Hajós, Cs. Szalai: Polimorfizmusok kontra ritka variánsok - hipotézismentes omikától a tudásgazdag adatelemzésig

Go to top